Eli Lilly falls after late-stage data for oral weight-loss drug

Viking Therapeutics

07/08/2025 11:48

Updates

** Shares of drugmaker Eli Lilly LLY.N fall 12% to $656.80 premarket

** Co reports late-stage data from its oral weight loss drug, orforglipron

** Orforglipron helped overweight or obese patients lose 12.4% of their body weight on average after 72 weeks in a late-stage study -LLY

** Says just over 10% of the high-dose patients dropped out of the trial due to adverse side effects

** Shares of smaller rival Viking Therapeutics VKTX.O, which is also developing an oral weight-loss drug, rose 14.5% to $36.5 premarket

** U.S.-listed shares of Danish rival Novo Nordisk NOVOb.CO rose 10% to $49.99 premarket

** Up to last close, LLY was down 3.3%, VKTX down ~21%, U.S.-listed shares of Novo down 47% YTD

 (Reporting by Mariam Sunny in Bengaluru)

 ((Mariam.ESunny@thomsonreuters.com;))